**Echinococcus multilocularis in Northern Hungary**

To the Editor: *Echinococcus multilocularis* infection is one of the most dangerous zoonoses in the Northern Hemisphere and causes more human death than rabies in Europe. Recent data indicate that *E. multilocularis* infection is spreading geographically and is being transmitted at an increasing rate in Europe (Figure). Since 1995, the parasite has been found in Poland, the Czech Republic, the Slovak Republic, Belarus, Hungary, and Romania; infections in humans have been increasing in frequency in central eastern Europe since the late 1990s (1–4). Since the 1990s, similar infection trends in foxes and humans have been observed in central western European countries, including eastern Austria, northern Germany, Denmark, the Netherlands, Luxembourg, and Belgium (1,2,5). Despite the increasing prevalence of *E. multilocularis* infection in foxes, the number of human cases did not vary in the historically known area (eastern France, Switzerland, southern Germany, and western Austria) during the 1990s (1), probably because of increased public awareness and control measures. In our previous study (2), the overall prevalence rate of infection was 16% (24/156) in the five northern counties of Hungary (Gyor-Sopron 30%, Nógrád 26%, Komárom-Esztergom 7%, Pest 6%, and Borsod-Abaúj-Zemplén 5%). This prevalence rate is similar to those observed in Poland, Belgium, and the Slovak Republic in recent years. In these countries, a total of 30 human cases have been reported since 1995 (3–6).

In Germany, infected foxes were more frequently found near water (7), which indicates a water-related natural cycle of the parasite. The spatial aggregation analysis of the parasite in intermediate hosts demonstrated that areas with humid conditions are at high risk for human exposure (8). In Europe, the most important water-related intermediate host of *E. multilocularis* is the water vole (*Arvicola terrestris*) (9). The prevalence of *E. multilocularis* in water voles can be as high as 39% in disease-endemic areas (10). Areas with high water-vole densities yielded a 10-fold higher risk for alveolar echinococcosis in humans compared to areas with low densities (10). These data indicate that water voles may play an important role in the epidemiology of *E. multilocularis*. All infected foxes included in this and the previous study (2) were found near permanent natural waters, i.e., in those areas where water vole populations exist, such as Lake Ferto, the River Danube, the River Ipoly, the River Rába, and several streams connected to the watershed area of the River Danube. *E. multilocularis* might have spread in the northern part of Hungary along the watershed area of the River Danube, coming from the known disease-endemic areas of Austria and the Slovak Republic. Similar spreading of the parasite along waterways was also observed in the Slovak Republic (11).

In the historically known *E. multilocularis*–endemic mountain areas, both fossorial and aquatic water voles exist (12). The density of these populations can be 10-fold greater than that of aquatic populations in other European countries (12). On the basis of the long incubation period of the parasite in humans (5–15 years) and the dates of the first human cases reported outside the historically known area (Figure), foxes might have reached the population density needed (13) to maintain the parasite cycle in low water-vole density areas in Europe from the 1980s (Figure). Although the parasite crossed the border of several countries that surrounds the known area, further spreading was not observed in those countries where *A. terrestris* is an endangered species (the Netherlands, northern Italy) or where water voles are absent from the fauna (western and southern France) (12).

The River Danube and several small streams crossing Budapest, the capital of Hungary with a population of 2 million, create ideal circumstances for urbanization of the life cycle of a parasite that involves water voles and red foxes. Urbanization of...
the life cycle of *E. multilocularis* was recently observed in Prague, the capital of the Czech Republic with a population of 1 million and similar hydrographic features (14); therefore, occurrences of this zoonosis should be continuously monitored in Budapest. Further studies are necessary to monitor the possible spread of the parasite in other regions that are thought to be currently free of the infection.

The regulatory, veterinary, and public health authorities of the European Union mobilized considerable financial and human resources to control rabies and paid less attention to alveolar echinococcosis in the 1990s, although incidence data indicate that alveolar echinococcosis is increasing and became an emerging infectious disease in Europe. In the Directive 2003/99/EC of the European Parliament and of the Council repealing Council Directive 92/117/EEC, echinococcosis has been added to the list of zoonoses to be monitored in the European Union countries. Effective methods to control *E. multilocularis* are unavailable; however, the zoonosis should be monitored and evaluated, and development of control programs should be intensified.

Acknowledgments

We thank Lajos Tekes and Vilmos Pálfí for supporting our studies and Károly Andi and Zsolt Tóth for their help in sample collection.

Tamás Sréter,* Zoltán Széll,* Zsuzsanna Sréter-Lancz,† and István Varga‡

*Central Veterinary Institute, Budapest, Hungary; †National Food Investigation Institute, Budapest, Hungary; and ‡Szent István University, Budapest, Hungary

References

1. Kern P, Bardonnet K, Renner E, Auer H, Pawlowski Z, Ammann RW, et al. European Echinococcosis Registry: Human alveolar echinococcosis, Europe, 1982–2000. Emerg Infect Dis. 2003;9:343–9.
2. Sréter T, Széll Z, Egyed Z, Varga I. *Echinococcus multilocularis*: an emerging pathogen in Central Eastern Europe and Hungary? Emerg Infect Dis. 2003;9:384–6.
3. KolárOVá L. *Echinococcus multilocularis*: new epidemiological insights in Central and Eastern Europe. Helminthologia. 1999;56:193–200.
4. Dubinský P, Várády M, Reiterová K, Miterpaková M, Turceková L. Prevalence of *Echinococcus multilocularis* in red foxes in the Slovak Republic. Helminthologia. 2001;38:215–9.
5. Losson B, Kervyn T, Detry J, Pastoret PP, Mignon B, Brochier B. Prevalence of *Echinococcus multilocularis* in the red fox (*Vulpes vulpes*) in southern Belgium. Vet Parasitol. 2003;117:23–8.
6. Myjak P, Nahorski W, Pietkiewicz H, von Nickisch-Rosenegk M, Stolarczyk J, Kacprzak E, et al. Molecular confirmation of human alveolar echinococcosis in Poland. Clin Infect Dis. 2003;37:121–5.
7. Staubach C, ThuIlke HH, TaCkmann K, Hughes-Jones M, Conraths FJ. Geographic information system-aided analysis of factors associated with the spatial distribution of *Echinococcus multilocularis* infections of foxes. Am J Trop Med Hyg. 2001;65:943–8.
8. Hansen F, Jeltsch F, TaCkmann K, Staubach C, ThuIlke HH. Processes leading to a spatial aggregation of *Echinococcus multilocularis* in its natural intermediate host Microtus arvalis. Int J Parasitol. 2004;34:37–44.
9. Viel JF, Giraudoux P, Abrial V, Bresson-Hadni S. Water vole (*Arvicola terrestris*) density as risk factor for human alveolar echinococcosis. Am J Trop Med Hyg. 1999;61:559–65.
10. Gottstein B, Saucy F, Deplazes P, Reichen J, Demierre G, Busato A, et al. Is high prevalence of Echinococcus multilocularis in wild and domestic animals associated with disease incidence in humans? Emerg Infect Dis. 2001;7:408–12.

11. Dubinský P, Miterpaková M, Hurniková Z, Tomasivcová O, Reiterová K, Várady M, et al. The role of red foxes (Vulpes vulpes) at spreading helminthozoonoses. Slovensk Vet Casopis. 2003;28:29–32.

12. Saucy F. The water vole as a pest: ecological variation, demography and population dynamics. In: Cowand DP, Feare CJ, editors. Advances in vertebrate pest management. Fürth, Bavaria: Filander Verlag; 1999. p. 25–42.

13. Chataun M, Pontier D, Artois M. Role of rabbits in recent demographic changes in red fox (Vulpes vulpes) populations in Europe. Mammalia. 2000;64:391–410.

14. Martinek K, Cerveny J. Echinococcus multilocularis in populations of the Czech urban foxes. Helminthologia. 2002;39:177.

Address for correspondence: Tamás Sréter, Department of Wildlife Diseases and Parasitology, Central Veterinary Institute, H-1149 Budapest, Tábornok u. 2, Hungary; fax: +36-1-2525177; email: sreter@oai.hu

Antimicrobial Resistance in Campylobacter

To the Editor: We wish to rectify several errors in our commentary, Antibiotics in Animal Feed and Spread of Resistant Campylobacter from Poultry to Humans (1). The fluoroquinolone enrofloxacin was approved in 1996 for therapeutic use by addition to drinking water upon the decision of a licensed veterinarian “for the control of mortality in chickens associated with Escherichia coli organisms and control of mortality in turkeys associated with E. coli and Pasteurella multocida organisms” (2). This therapeutic use was withdrawn (3) but is now under appeal. Initial approval and subsequent efforts to withdraw use of enrofloxacin in the United States parallel the earlier trend in Europe and specifically Denmark, where the use of antimicrobial agents as growth promoters has been banned (4).

Enrofloxacin is not approved for prophylactic or growth promotion use in poultry feed as stated in our commentary and in the first section of the flowchart (1). However, when enrofloxacin is added to the drinking water of poultry, large numbers of both ill and healthy animals are exposed to the agent (5). Although extra-label use of enrofloxacin is prohibited, microbiologic culture of either of the cited bacteria is not required before administration (2). Despite the restrictions on enrofloxacin use, emergence of fluoroquinolone-resistant Campylobacter species, with poultry as an important source, has been documented in the United States (5,6). Thus the decision to withdraw therapeutic use of enrofloxacin (3) was warranted. Therefore, our conclusion remains: use of enrofloxacin in poultry materially contributed to increase in human infection by fluoroquinolone-resistant Campylobacter species. Given the above, our commentary should have been entitled Use of Antibiotics in the Poultry Industry and Spread of Resistant Campylobacter to Humans. We regret the errors and hope we have clarified this issue.

Nicole M. Iovine* and Martin J. Blaser†
*New York University School of Medicine, New York, New York, USA; †New York Harbor Department of Veterans Affairs Medical Center, New York, New York, USA

References:

1. Iovine N, Blaser MJ. Antibiotics in animal feed and spread of resistant Campylobacter from poultry to humans. Emerg Infect Dis. 2004;10:1158–9.

2. Sundlof S. Enrofloxacin for Poultry; Opportunity for Hearing. Department of Health and Human Services, Food and Drug Administration, Center for Veterinary Medicine. Fed Register. 2000;65:64954–65.

3. Davidson D. In the matter of enrofloxacin for poultry: withdrawal of approval of Bayer Corporation’s new animal drug application 1 (NADA) 140-828 (Baytril). FDA Docket No 00N-1571 2004.

4. DANMAP 2002. Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, foods and humans in Denmark. Copenhagen Danish Zoonosis Center, Danish Veterinary Institute. 2003.

5. Gupta A, Nelson JM, Barrett TJ, Tauxe RV, Rossiter SP, Friedman CR, et al. Antimicrobial resistance among Campylobacter strains, United States, 1997–2001. Emerg Infect Dis. 2004;10:1102–9.

6. Smith KE, Besser JM, Hedberg CW, Leano FT, Bender JB, Wicklund JH, et al. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992–1998. Investigation Team. N Engl J Med. 1999;340:1525–32.

Address for correspondence: Martin J. Blaser, Department of Medicine, NYU School of Medicine, 550 First Avenue, OBV-606, New York, NY 10016, USA; fax: 212-263-3969; email: martin.blaser@med.nyu.edu

Search past issues of EID at www.cdc.gov/eid